

This document has been translated from a Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. RaQualia Pharma Inc. assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Securities code: 4579
March 25, 2019

Naoki Tani
President & CEO
RaQualia Pharma Inc.
1-21-19 Meieki Minami,
Nakamura-ku, Nagoya, Japan

NOTICE OF RESOLUTIONS AT THE 11TH ORDINARY GENERAL MEETING OF SHAREHOLDERS

Dear Shareholders:

We hereby inform you that the following matters were reported and resolved at the 11th Ordinary General Meeting of Shareholders of RaQualia Pharma Inc. held today.

- Report matters:**
1. The Business Report and the Consolidated Financial Statements for the 11th Fiscal Year (January 1, 2018 to December 31, 2018), and the results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee
 2. Non-consolidated Financial Statements for the 11th Fiscal Year (January 1, 2018 to December 31, 2018)

We reported on the content of 1 and 2 above.

Resolution matters:

Proposal 1:

Reduction in Amount of Capital Stock

This proposal was approved and adopted as proposed and capital stock of ¥2,793,458,488 will be reduced by ¥892,842,971 to ¥1,900,615,517. The total amount of the reduction will be transferred to other capital surplus. The effective date of reduction in amount of capital stock is scheduled on May 1, 2019.

Proposal 2:

Reduction in Amount of Legal Capital Surplus

This proposal was approved and adopted as proposed and legal capital surplus of ¥2,983,241,487 will be reduced by ¥892,842,971 to ¥2,090,398,516. The total amount of the reduction will be transferred to other capital surplus. The effective date of reduction in amount of legal capital surplus is scheduled on May 1, 2019.

Proposal 3:

Appropriation of Surplus

This proposal was approved and adopted as proposed and the entire amount of other capital surplus generated by the reduction of capital stock of Proposal 1 as well as the reduction of legal capital surplus of Proposal 2 will be transferred to retained earnings brought forward in order to cover the loss. The effective date of appropriation of surplus is scheduled on May 1, 2019.

Proposal 4: Election of Four (4) Directors (excluding Directors Serving on the Audit and Supervisory Committee)

This proposal was approved and adopted as proposed and Mr. Naoki Tani, Mr. Hatsuo Aoki, Mr. Kiichiro Kawada and Mr. Shuzo Watanabe were reelected as Directors (excluding Directors serving on the Audit and Supervisory Committee) and each assumed office.
Mr. Hatsuo Aoki is an Outside Director.

About the Company's Officer System

By a resolution passed at the meeting of the Board of Directors that was held after the General Meeting, the Company's Director and Vice President system on and after March 25, 2019, was decided as follows.

Director	Representative Director	Naoki Tani
	Director (Outside Director)	Hatsuo Aoki
	Director	Kiichiro Kawada
	Director	Shuzo Watanabe
	Audit and Supervisory Committee Member (Outside Director)	Shinnosuke Maki
	Audit and Supervisory Committee Member (Outside Director)	Hisaji Agata
	Audit and Supervisory Committee Member (Outside Director)	Gakuji Nomoto
	Vice President	Executive Vice President
	Senior Vice President	Shuzo Watanabe
	Vice President	Yasuhiro Takamatsu
	Vice President	Kaoru Shimada